Skip to main content
. 2023 Aug 9;159(9):977–985. doi: 10.1001/jamadermatol.2023.2609

Figure 1. Clinical Efficacy of Nemolizumab.

Figure 1.

A, Baseline Peak Pruritus Numerical Rating Scale (PP-NRS) scores and percentage of patients with no response to placebo and those with a response to nemolizumab treatment at week 4. A successful response according to the PP-NRS was defined as a decrease (improvement) of 4 points from baseline. Horizontal lines indicate mean. B, Baseline investigator global assessment (IGA) scores and percentage of placebo and nemolizumab group patients with IGA success at week 18. A successful response according to the IGA was defined as a score of 0 or 1 plus a decrease (improvement) of 2 points from baseline. Error bars indicate SD.

aP < .001.